Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0042373 (
vascular disease
)
17,070
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
IUGR can develop, either in response to a reduced IGP or in response to a deficient transplacental supply of O2 and nutrients. Particularly, insight in the pathogenesis of extrinsic IUGR is important for the clinician to offer him tools for a more causal treatment. Extrinsic IUGR is usually preceded by a gradually developing uteroplacental insufficiency. Uteroplacental hypoperfusion may represent the common starting point for extrinsic IUGR and maternal systemic symptomatology (
PIH
, (pre)eclampsia). In addition, it may be the common endpoint of two different (subclinical) pathways: defective trophoblast differentiation ("primary") and decompensation of early-pregnancy circulatory maladaptation ("secondary"). From a theoretical point of view, the primary pathway may develop at a slower rate. Therefore, the primary pathway is more likely to result in extrinsic IUGR. In contrast, the secondary pathway assumes decompensation of an initially maladapted maternal circulation. This implies a highly variable rate of development and with it, severity of clinical symptomatology. It also indicates that the the pathogenesis, eventually leading to manifest
vascular disease
, is superimposed on a pre-existent inadequacy in maternal hemodynamics, renal function and/or volume homeostasis. It is understood that intertwining of these two pathways is common. Unfortunately, our current knowledge, about placentation and the concomitant early-pregnancy adjustments is poor. Current research of trophoblast differentiation and of the concomitant maternal end-organ effects in normal and pathologic pregnancy, is likely to increase our understanding of the first-trimester phenomena preceding IUGR soon.
...
PMID:The effect of early maternal maladaptation on fetal growth. 793 12